Can CAR-T and gene therapy cures really sustain biopharma? Not for all, analyst says
admin 12th April 2018 Uncategorised 0Ever since Novartis invested in personalized CAR-T cancer treatments more than five years ago, analysts have pondered a difficult question: How can pharma companies profit from curing patients with gene and cell therapies? This week, Goldman Sachs resurrected that burning question.
More: Can CAR-T and gene therapy cures really sustain biopharma? Not for all, analyst says
Source: fierce